Related Experiment Video
Updated: Oct 25, 2026

Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy
Published on: November 30, 2018
Fibrinogen and D-dimer alterations in thyroid dysfunction: implications for bleeding and thrombotic risk
Befikad Mandefro1, Amanuel Kelem2, Tiruneh Adan3
1Department of Medical Laboratory Sciences, College of Medicine and Health Sciences, Debre Berhan University, Debre Berhan, Ethiopia. befikadm@gmail.com.
Abstract:
Thyroid dysfunction can disrupt the balance of the hemostatic system, predisposing affected individuals to either bleeding or thrombotic complications, depending on the nature and severity of the disorder. In hyperthyroidism, a prothrombotic state is commonly observed, characterized by increased fibrinogen concentrations, elevated D-dimer levels, and enhanced coagulation activation. Conversely, hypothyroidism may impair coagulation and fibrinolysis, resulting in variable bleeding or thrombotic manifestations depending on disease severity. Raised D‑dimer levels reflect increased thrombin generation with secondary fibrinolysis and therefore serve as markers of a hypercoagulable state. Fibrinogen concentrations above 4.0 g/L are independently associated with a higher risk of venous thromboembolism, although a direct causal role has not been established. In patients with hyperthyroidism, fibrinogen levels are increased by approximately 20% on average, suggesting an elevated thrombotic risk, potentially mediated by reduced fibrinolytic capacity. Hyperthyroid patients consistently demonstrate higher plasma D‑dimer concentrations, indicating concurrent activation of coagulation and fibrinolysis. Previous studies have documented increased D‑dimer levels in both overt and subclinical hyperthyroidism, consistent with upregulation of the fibrinolytic pathway. D‑dimer values in the range of approximately 450-650 ng/mL are frequently observed in this population. In moderate hypothyroidism, relatively lower D‑dimer levels have been linked to diminished fibrinolytic activity. Bleeding manifestations have been frequently reported in patients with hypothyroidism, although their prevalence varies considerably depending on the study population and clinical criteria used. In contrast, thrombotic complications are more commonly associated with hyperthyroidism, with reported frequencies varying widely across studies due to differences in disease severity, population characteristics, and outcome definitions. In summary, thyroid dysfunction disturbs hemostatic equilibrium and leads to characteristic changes in fibrinogen and D‑dimer levels. Abnormal concentrations of these markers may signal impaired hemostatic function and could help identify patients at increased risk of bleeding or thrombosis.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Graves Disease II: Pathophysiology
Functions of Thyroid Hormones
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
